Beecham Group Plc

Adprotech Limited

Ian Dodd

Jeffery H Robinson

Richard Anthony Godwin Smith

Richard Anthony Smith

Anne Mary Freeman

Danuta Ewa Mossakowska

Danuta Ewa Irena Mossakowska

Danuta Ewa Irena Mossakowkska

The present invention provides, among other things, soluble derivatives of soluble polypeptides that incorporate membrane binding elements. Methods of making these soluble derivatives, and methods of using these soluble derivatives also are provided.

Conjugates of soluble peptidic compounds with membrane-binding agents

Soluble polypeptides are provided that comprise no more than three short consensus repeats (SCR) of Complement Receptor 1, and contain SCR3. DNA molecules encoding such soluble polypeptides, as well as methods, vectors and host cells, also are provided.

Soluble CR1 derivatives

A purified fibrinolytically active degraded species of tissue-type plasminogen activator comprising a fibrinolytically intact B chain of native t-PA linked to kringle 2 as the only functionally and structurally intact domain of native t-PA A chain.

Human tissue plasminogen activator consisting essentially of t-PA

A fibrinolytically active hybrid protein which comprises one chain of a 2-chain protease linked to a chain of a different 2-chain protease, or to the same chain of the same protease, at least one of the chains in the hybrid protein being derived from a fibrinolytically active protease, such that the hybrid protein has a catalytic site essential for fibrinolytic activity which is optionally blocked by a removable blocking group.

Tissue plasminogen activator A-chain/urokinase B-chain hybrid protein

Reversibly blocked plasmin, t-PA hybrid fibrinolytic enzymes and

A hybrid protein which comprises plasmin A-chain linked to urokinase B-chain, the catalytic site of which is blocked by a removable blocking group.

Growing community of inventors

Buckland, United Kingdom

Ian Dodd